All-trans retinoic acid downregulates ALK in neuroblastoma cell lines and induces apoptosis in neuroblastoma cell lines with activated ALK

Cancer Letters

Volumn 297, Issue 2, 2010, Pages 220-225

  Futami, Hitoyasu ^a   Sakai, Ryuichi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

ALK; ATRA; Neuroblastoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; RETINOIC ACID; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; GENE ACTIVATION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL GROWTH; DRUG EFFECTS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; NEUROBLASTOMA; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; TRETINOIN; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 77956415439     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.05.014     Document Type: Article

References (26)

1. Maris J.M., Matthay K.K. Molecular biology of neuroblastoma. J. Clin. Oncol. 1999, 17:2264-2279.
2. Sidell N. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J. Natl. Cancer Inst. 1982, 68:589-596.
3. Thiele C.J., Reynolds C.P., Israel M.A. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985, 313:404-406.
4. Abemayor E., Chang B., Sidell N. Effects of retinoic acid on the in vivo growth of human neuroblastoma cells. Cancer Lett. 1990, 55:1-5.
5. Reynolds C.P., Matthay K.K., Villablanca J.G., Maurer B.J. Retinoid therapy of high-risk neuroblastoma. Cancer Lett. 2003, 197:185-192.
6. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., Swift P., Shimada H., Black C.T., Brodeur G.M., Gerbing R.B., Reynolds C.P. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid, Children's Cancer Group. New Engl. J. Med. 1999, 341:1165-1173.
7. Matthay K.K., Reynolds C.P., Seeger R.C., Shimada H., Adkins E.S., Haas-Kogan D., Gerbing R.B., London W.B., Villablanca J.G. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J. Clin. Oncol. 2009, 27:1007-1013.
8. Ponzoni M., Bocca P., Chiesa V., Decensi A., Pistoia V., Raffaghello L., Rozzo C., Montaldo P.G. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res. 1995, 55:853-861.
9. Melino G., Thiele C.J., Knight R.A., Piacentini M. Retinoids and the control of growth/death decisions in human neuroblastoma cell lines. J. Neurooncol. 1997, 31:65-83.
10. Voigt A., Zintl F. Effects of retinoic acid on proliferation, apoptosis, cytotoxicity, migration, and invasion of neuroblastoma cells. Med. Pediatr. Oncol. 2003, 40:205-213.
11. Niizuma H., Nakamura Y., Ozaki T., Nakanishi H., Ohira M., Isogai E., Kageyama H., Imaizumi M., Nakagawara A. Bcl-2 is a key regulator for the retinoic acid-induced apoptotic cell death in neuroblastoma. Oncogene 2006, 25:5046-5055.
12. Shiota M., Fujimoto J., Semba T., Satoh H., Yamamoto T., Mori S. Hyperphosphorylation of a novel 80kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 1994, 9:1567-1574.
13. Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G., Shapiro D.N., Saltman D.L., Look A.T. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994, 263:1281-1284.
14. Griffin C.A., Hawkins A.L., Dvorak C., Henkle C., Ellingham T., Perlman E.J. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 1999, 59:2776-2780.
15. Jazii F.R., Najafi Z., Malekzadeh R., Conrads T.P., Ziaee A.A., Abnet C., Yazdznbod M., Karkhane A.A., Salekdeh G.H. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J. Gastroenterol. 2006, 12:7104-7112.
16. Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L., Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X., Gygi S.P., Gu T.L., Polakiewicz R.D., Rush J., Comb M.J. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
17. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S., Watanabe H., Kurashina K., Hatanaka H., Bando M., Ohno S., Ishikawa Y., Aburatani H., Niki T., Sohara Y., Sugiyama Y., Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
18. Miyake I., Hakomori Y., Shinohara A., Gamou T., Saito M., Iwamatsu A., Sakai R. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 2002, 21:5823-5834.
19. Osajima-Hakomori Y., Miyake I., Ohira M., Nakagawara A., Nakagawa A., Sakai R. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am. J. Pathol. 2005, 167:213-222.
20. Chen Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M., Wang L., Soda M., Kikuchi A., Igarashi T., Nakagawara A., Hayashi Y., Mano H., Ogawa S. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 455:971-974.
21. George R.E., Sanda T., Hanna M., Frohling S., Luther W., Zhang J., Ahn Y., Zhou W., London W.B., McGrady P., Xue L., Zozulya S., Gregor V.E., Webb T.R., Gray N.S., Gilliland D.G., Diller L., Greulich H., Morris S.W., Meyerson M., Look A.T. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008, 455:975-978.
22. Janoueix-Lerosey I., Lequin D., Brugieres L., Ribeiro A., de Pontual L., Combaret V., Raynal V., Puisieux A., Schleiermacher G., Pierron G., Valteau-Couanet D., Frebourg T., Michon J., Lyonnet S., Amiel J., Delattre O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008, 455:967-970.
23. Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P., Laureys G., Speleman F., Kim C., Hou C., Hakonarson H., Torkamani A., Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M., Maris J.M. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455:930-935.
24. Smith M.A., Parkinson D.R., Cheson B.D., Friedman M.A. Retinoids in cancer therapy. J. Clin. Oncol. 1992, 10:839-864.
25. Smith M.A., Adamson P.C., Balis F.M., Feusner J., Aronson L., Murphy R.F., Horowitz M.E., Reaman G., Hammond G.D., Fenton R.M., et al. Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. J. Clin. Oncol. 1992, 10:1666-1673.
26. Villablanca J.G., Khan A.A., Avramis V.I., Seeger R.C., Matthay K.K., Ramsay N.K., Reynolds C.P. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J. Clin. Oncol. 1995, 13:894-901.